Kim Donghee, Danpanichkul Pojsakorn, Wijarnpreecha Karn, Cholankeril George, Loomba Rohit, Ahmed Aijaz
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Aliment Pharmacol Ther. 2025 Mar;61(5):891-894. doi: 10.1111/apt.18501. Epub 2025 Jan 11.
Our study investigated the prevalence of lean steatotic liver disease (SLD) and its subcategories, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-related and alcohol-related SLD (MetALD), and alcohol-related liver disease (ALD) among lean adults in the US. Analysing data from 2965 lean adults (≥ 18 years) from the National Health and Nutrition Examination Survey (2017-2023), we found the age-adjusted prevalence of lean SLD to be 12.8%. Specifically, the prevalence was 9.3% for lean MASLD, 1.3% for MetALD and 1.0% for ALD. Notably, within the MASLD group, significant fibrosis, advanced fibrosis, and cirrhosis were observed in 5.6%, 2.4% and 2.0%, respectively.
我们的研究调查了美国瘦成年人中瘦型脂肪性肝病（SLD）及其亚类的患病率，包括代谢功能障碍相关脂肪性肝病（MASLD）、代谢功能障碍相关和酒精相关的SLD（MetALD）以及酒精性肝病（ALD）。通过分析来自国家健康和营养检查调查（2017 - 2023年）的2965名瘦成年人（≥18岁）的数据，我们发现瘦型SLD的年龄调整患病率为12.8%。具体而言，瘦型MASLD的患病率为9.3%，MetALD为1.3%，ALD为1.0%。值得注意的是，在MASLD组中，分别有5.6%、2.4%和2.0%的患者观察到显著纤维化、进展性纤维化和肝硬化。
